Search Results

You are looking at 281 - 290 of 493 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer

Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven

improvements seen in the ToGA trial (2011) for trastuzumab and the RAINBOW trial (2016) for paclitaxel and ramucirumab. 4 , 8 Among patients with gastric cancer receiving systemic therapy, the survival benefits were largest in the best-case (p10; 4.7 months

Full access

Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer . J Clin Oncol 2005 ; 23

Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

intravenously in patients with recurrent SCLC. 29 – 31 Based on phase II trials, a number of other agents have been recommended as options for subsequent systemic therapy in patients with relapsed disease, including irinotecan, paclitaxel, docetaxel

Full access

A US Registry–Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich

.5%–97.5%]) are very similar to those from a phase II, prospective, nonrandomized study of weekly adjuvant paclitaxel in combination with trastuzumab for 12 weeks, followed by maintenance trastuzumab for 1 year in patients with node-negative, HER2-positive breast

Full access

Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy

Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl

). Since 2000, standard provincial treatment in chemo-WART group consisted of 3 cycles of carboplatin (area under the curve [AUC], 5–6) and paclitaxel (175 mg/m 2 ) every 3 to 4 weeks followed by abdominopelvic irradiation. RT was initiated 3 to 4 weeks

Full access

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Bin Wu and Lizheng Shi

shown promising results in early trials. 31 , 32 However, there is a dearth of information regarding the economic outcome of maintenance treatments for MPC. Although 2 previous economic analyses have shown that a chemotherapy regimen containing nab-paclitaxel

Full access

Biologics in Cervical Cancer Therapy

Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk

patients to 4 arms, 2 of which include combination chemotherapeutic regimens that were found to have benefit in the study population (paclitaxel/cisplatin vs. paclitaxel/topotecan) compared with these regimens plus bevacizumab ( Table 1 ). All medication

Full access

Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety

Adrienne G. Waks and Ann H. Partridge

-mutated patients. 17 Of relevance to HER2-positive patients, available data suggest no significant additive impact on amenorrhea from 1 year of trastuzumab therapy, 12 and the CRA rate associated with paclitaxel/trastuzumab (TH) for women with small HER

Full access

Life After Treatment: Quality-of-Life Concerns in Patients Treated for Cancer

Mindy E. Goldman

chemotherapy regimen, cumulative dose, and patient age. Most ovarian toxicity is due to alkylating agents, with moderate effects from doxorubicin or cisplatin and fewer effects from fluorouracil, methotrexate, vincristine, paclitaxel, and docetaxel. This

Full access

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian, and Jillian Scavone

alternative in this setting. Agents recommended by the panel for treating advanced recurrent/metastatic disease include cisplatin, carboplatin, paclitaxel (category 2B), and erlotinib (category 2B) as single agents and cisplatin/vinorelbine, cisplatin/paclitaxel